---
schema_version: "secwatch.filing_event.v1"
accession: "0000785161-22-000050"
form_type: "8-K"
ticker: "EHC"
cik: "0000785161"
company_name: "Encompass Health Corp"
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:43:21.904749+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Encompass Health reaffirms FY2022 guidance at Mizuho CEO Insight Series

## Summary
- Reiterates FY2022 net operating revenues guidance of $4.32B to $4.35B.
- Reaffirms adjusted EBITDA guidance of $800M to $820M.
- Reaffirms adjusted EPS from continuing ops guidance of $2.71 to $2.86.
- CEO Mark Tarr participating in Mizuho CEO Insight Series on Nov 14, 2022.

## SEC filing metadata
- accession: 0000785161-22-000050
- form_type: 8-K
- ticker: EHC
- cik: 0000785161
- company_name: Encompass Health Corp
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/785161/000078516122000050/0000785161-22-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/785161/000078516122000050/ehc-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000785161-22-000050
- JSON: https://secwatch.observer/filing/0000785161-22-000050.json
- Plain text: https://secwatch.observer/filing/0000785161-22-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.